Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2016

View Archived Issues

Plasma, urine and ligament tissue metabolites as potential biomarkers of ankylosing spondylitis

New PDE4 inhibitor blocks proinflammatory effects in plasma and CNS

MabVax Therapeutics reports progress in MVT-5873 and MVT-2163 programs

Resunab demonstrates clinical benefit in phase II trial in systemic sclerosis

Novel optimized mouse model of cyclophosphamide-induced bone marrow suppression

RXFP1 agonist ML-290 as a potential treatment for acute myocardial infarction

Full results of EUCLID trial of ticagrelor in peripheral artery disease trial divulged

Seegene and Institut Catala d'Oncologia collaborate on cancer diagnostics

CellMax-DNA Genetic Cancer Risk Test available in India

FDA gives fast track designation to Centrexion Therapeutics' CNTX-4975 for Morton's neuroma

Bristol-Myers Squibb and Enterome establish microbiome-focused immuno-oncology collaboration

AstraZeneca reviews highlights of third quarter 2016

OSE Immunotherapeutics and Selexis enter cancer immunotherapy, autoimmune disease collaboration

Otsuka announces pipeline developments of third quarter 2016

Aurora Diagnostics selected to provide Ventana PD-L1 Assay in U.S.

BLA submission for bevacizumab biosimilar ABP-215

Arena Pharmaceuticals patents 5-HT2C receptor agonists

Clearside Biomedical enrolls first patient in HULK study

ImmunoMet Therapeutics discloses OXPHOX inhibitors

Rhizen initiates phase I/IIa study of RP-3128 for asthma

H. Lundbeck describes PDE1 inhibitors

Bayer Pharma develops t-PA inhibitors

Medshine Discovery presents EGFR inhibitors

Modus Therapeutics gives update on phase II sevuparin study in sickle cell disease

ACADIA Pharmaceuticals begins phase II ADVANCE trial of pimavanserin

Albireo Pharma's A-4250 accepted into PRIME program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...